Poseida Therapeutics, Inc.

111 articles with Poseida Therapeutics, Inc.

• Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022

  3/9/2023

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the fourth quarter and full year ended December 31, 2022.  

• Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board

  3/1/2023

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB).

• Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

  2/22/2023

  Poseida Therapeutics, Inc. today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT.

• Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference

  2/14/2023

  Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced that the Company's Chief Executive Officer, Mark Gergen, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET.

• Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023

  2/8/2023

  Poseida Therapeutics, Inc. today announced that the Company will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday, February 22, 2023.

• Poseida Therapeutics Announces Board Change - Jan 31, 2023

  1/31/2023

  Poseida Therapeutics, Inc. announced that Eric Ostertag, M.D., Ph.D., has resigned as Executive Chairman and will retire from the Board of Directors effective February 3, 2023.

• Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition

  12/11/2022

  Poseida Therapeutics, Inc. announced that the Company will present preclinical data from its P-FVIII-101 gene therapy program, partnered with Takeda, at the 2022 American Society of Hematology Annual Meeting being held in New Orleans and virtually December 10–13, 2022.

• Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress

  12/6/2022

  Poseida Therapeutics, Inc. today announced it will present early clinical results from its Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.

• Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022

  11/10/2022

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced business updates and financial results for the third quarter ended September 30, 2022.  

• Poseida Therapeutics to Present at Two Upcoming Investor Conferences

  11/8/2022

  Poseida Therapeutics, Inc. today announced that the Company will participate in the following upcoming investor conferences.

• Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress

  11/3/2022

  Poseida Therapeutics, Inc. announced the acceptance of two poster presentations at the European Society for Medical Oncology Immuno-Oncology 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.

• Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition

  11/3/2022

  Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced that preclinical data from its P-FVIII-101 program, partnered with Takeda, has been selected for an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, being held in New Orleans and virtually December 10–13, 2022.

• Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting

  10/5/2022

  Poseida Therapeutics, Inc. today announced that it will present a Trial in Progress poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held in Boston and virtually from November 8 –12, 2022.

• Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Poseida Therapeutics, Inc. (Nasdaq: PSTX), today announced that the Company's Chief Financial Officer, Johanna Mylet, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY from September 12-14, 2022.

• Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022

  8/11/2022

  Poseida Therapeutics, Inc. announced business updates and financial results for the second quarter ended June 30, 2022.

• Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  8/8/2022

  Poseida Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $3.50 per share, including 3,000,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares.

• Poseida Therapeutics Announces Proposed Public Offering of Common Stock - Aug 04, 2022

  8/4/2022

  Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that it has commenced an underwritten public offering of shares of its common stock.

• Poseida Therapeutics Announces Pricing of Public Offering of Common Stock - Aug 04, 2022

  8/4/2022

  Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.50 per share.

• Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies

  8/3/2022

  Poseida Therapeutics, Inc. today announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies.

• Poseida Therapeutics Announces Proposed Public Offering of Common Stock - Aug 03, 2022

  8/3/2022

  Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that it has commenced an underwritten public offering of shares of its common stock.